PT - JOURNAL ARTICLE AU - Jeffery, Molly Moore AU - Ahadpour, Mitra AU - Allen, Summer AU - Araojo, Richardae AU - Bellolio, Fernanda AU - Chang, Nancy AU - Ciaccio, Laura AU - Emanuel, Lindsay AU - Fillmore, Jonathan AU - Gilbert, Gregg H. AU - Koussis, Patricia AU - Lee, Christine AU - Lipkind, Heather AU - Mallama, Celeste AU - Meyer, Tamra AU - Moncur, Megan AU - Nuckols, Teryl K. AU - Pacanowski, Michael A. AU - Page, David B. AU - Papadopoulos, Elektra AU - Ritchie, Jessica D. AU - Ross, Joseph S. AU - Shah, Nilay D. AU - Soukup, Mat AU - St. Clair, Christopher O. AU - Tamang, Stephen AU - Torbati, Sam S. AU - Wallace, Douglas W. AU - Zhao, Yueqin AU - Heckmann, Rebekah TI - Acute Pain Pathways: protocol for a prospective cohort study AID - 10.1101/2021.10.21.21265156 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.21.21265156 4099 - http://medrxiv.org/content/early/2021/10/25/2021.10.21.21265156.short 4100 - http://medrxiv.org/content/early/2021/10/25/2021.10.21.21265156.full AB - Introduction Opioid analgesics are often used to treat moderate-to-severe acute non-cancer pain; however, there is little high-quality evidence to guide clinician prescribing. An essential element to developing evidence-based guidelines is a better understanding of pain management and pain control among individuals experiencing acute pain for various common diagnoses.Methods and analysis This multi-center prospective observational study will recruit 1,550 opioid-naïve participants with acute pain seen in diverse clinical settings including primary/urgent care, emergency departments, and dental clinics. Participants will be followed for 6 months with the aid of a patient-centered health data aggregating platform that consolidates data from study questionnaires, electronic health record data on health care services received, prescription fill data from pharmacies, and activity and sleep data from a Fitbit activity tracker. Participants will be enrolled to represent diverse races and ethnicities and pain conditions, as well as geographical diversity. Data analysis will focus on assessing patients’ patterns of pain and opioid analgesic use, along with other pain treatments; associations between patient and condition characteristics and patient-centered outcomes including resolution of pain, satisfaction with care, and long-term use of opioid analgesics; and descriptive analyses of patient management of leftover opioids.Ethics and dissemination This study has received approval from IRBs at each site. Results will be made available to participants, funders, the research community, and the public.Trial registration number NCT04509115Strengths and limitations of this studyThis study addresses a key knowledge gap by recruiting a large and diverse group of patients with acute pain, following them for 6 months, and prospectively assessing their pain experience and acute pain treatmentPatients will be recruited from multiple treatment settings that are important in the treatment of acute pain, including emergency departments, primary care, dental settings, and surgical settings.A patient-centered health data aggregating platform reduces the patient burden of participating in the trial by allowing participants to complete questionnaires when it is convenient and by automatically collecting data on physical activity, healthcare service use, and prescription fillsAll participants will have been offered an opioid prescription, reducing the ability to compare outcomes across opioid and non-opioid pain medicationsDespite a large sample size, there may be limited numbers of specific acute pain diagnoses with a sufficient sample to analyze and compare by condition/diagnosisCompeting Interest StatementIn the past three years, Dr. Jeffery has received unrelated grant funding from the Agency for Healthcare Research and Quality, the National Institute on Drug Abuse, the National Heart, Lung, and Blood Institute, the American Cancer Society and the US Food and Drug Administration for the Yale-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI) (U01FD005938). Dr. Ross received research support through Yale University from the Laura and John Arnold Foundation for the Collaboration for Research Integrity and Transparency (CRIT) at Yale; Dr. Ross currently receives research support through Yale University from Johnson and Johnson to develop methods of clinical trial data sharing, from the Medical Device Innovation Consortium as part of the National Evaluation System for Health Technology (NEST), from the Food and Drug Administration for the Yale-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI) (U01FD005938), from the Agency for Healthcare Research and Quality (R01HS022882), from the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) (R01HS025164, R01HL144644), and from the Laura and John Arnold Foundation to establish the Good Pharma Scorecard at Bioethics International. Ms. Ritchie currently receives research support through Yale University from Johnson & Johnson to develop methods of clinical trial data sharing, from the Medical Device Innovation Consortium as part of the National Evaluation System for Health Technology (NEST), and from the US Food and Drug Administration for the Yale-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI) (U01FD005938). Ms. Emanuel currently receives research support from the Medical Device Innovation Consortium as part of the National Evaluation System for Health Technology (NEST) and from the US Food and Drug Administration for the Yale-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI) (U01FD005938). Dr. Gilbert currently receives research support from the National Institutes of Health (U19DE028717). Dr. Bellolio received funding from the National Center for Complementary and Integrative Health, the National Institute on Aging, and Diagnostic Robotics. Dr. Heckmann reported receiving salary support from CMS to develop, implement, and maintain hospital performance outcome measures that are publicly reported, in addition to receiving research support through Yale as part of a Centers for Disease Control and Prevention project designed to strengthen prescription drug overdose prevention efforts, from Connecticut Department of Public Health as part of a public health project designed to assess the impact of Good Samaritan Laws, and from the Community Health Network of Connecticut for her work as a medical consultant. Dr Lipkind serves on the Pfizer independent external data monitoring committee for the COVID-19 vaccine. Ms. Ciaccio is an employee of Hugo Health. No other authors report any relevant payments or services.Funding StatementThis publication is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award [Center of Excellence in Regulatory Science and Innovation grant to Yale University and Mayo Clinic, U01FD005938] totaling $6,119,692 with 100 percent funded by FDA/HHS. The contents are those of the authors and do not necessarily represent the official views of, nor an endorsement, by FDA/HHS, or the U.S. Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRBs of Mayo Clinic, Yale University, University of Alabama-Birmingham, Cedars-Sinai, and Monument Health gave ethical approval for the workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are not available to the public